spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

PCI Pharma Services

PCI secures third site for Clinical Trials storage, central logistics and distribution center

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.

The San Diego site is one of PCI’s eight global Clinical locations across the US, EU and Asia Pacific regions – supporting Clinical Trials in more than 100 countries around the world.

PCI’s new two-story 38,000 sq ft state of the art facility – located less than a mile from its existing San Diego campus – will serve as PCI’s main storage, logistics and distribution center on the West Coast. Beyond controlled room temperature, the building will be equipped for Cold Chain requirements for 2-8°C, -20°C, and -80°C with expanded ultra-low freezer capabilities, as well as cryogenic liquid nitrogen storage at -196°C.

The site expansion project will be completed and validated during the fourth quarter of 2019.

PCI’s Mark Shepanski, Executive Director of Operations and Site Lead for San Diego, said: “Securing our third site in San Diego allows us to continue to provide industry-leading reliability, flexibility and quality in clinical supply management services.

“We began to investigate our requirements for the additional facility last year, anticipating our customers would eventually need additional storage space for their larger Clinical studies. As our customers experience continued success, we want to make sure we adapt and grow with them.”

This announcement is the latest reflecting PCI’s commitment to the continued development and expansion of its global clinical supply network in anticipation of future customer needs; a strategy which includes ongoing and considerable capital investment in facilities and increased capacity.

To find out more, please visit here.

About PCI
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our customers view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives.

For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact
Tom Gosschalk / Carrie Lowe at BECG
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

3P Biopharmaceuticals receives FDA approval

[Pamplona, September 16th, 2019] 3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in process development and GMP manufacturing of biologics, receives FDA approval after completing the Pre-Approval Inspection (PAI) conducted at the 3P drug substance manufacturing facility.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement